and are therefore not quoted.
Gonadotrophins were measured in 24-hr. collections of urine during the 2 days of treatment with ACTH and for 1 day before and 1 day after. They were measured both as total gonadotrophin and as follicle-stimulating hormone (FSH) by methods used previously (Brown, 1963) and the results are expressed in terms of the inter¬ national reference preparation for human menopausal gonadotrophin (IRP).
The results for total gonadotrophin (Table 1) show that in seven of the eight cases there was a rise on the first day of treatment with ACTH. A i-test showed the rise to be significant (t = 3-51, P < 0-01). The mean total gonadotrophin also exceeded the control level on the second day of treatment, but there was a greater scatter so that in a comparison with the pre-treatment day the value of t was 2-27 (for P = 0-05, t would be 2-37). On the day after treatment the mean urinary gonadotrophin had returned to the pre-treatment level. The values for gonadotrophin measured as FSH showed a similar pattern and are not included in the table.
These results show a rapid increase in the urinary excretion of gonadotrophin on treatment with ACTH. Recently Crean, Bell, Card, Loraine & Sircus (1963) have suggested that a rise in the level of urinary gonadotrophin in patients treated with ACTH for ulcerative colitis may be due to the improvement in their general condition. The response in the present series was too rapid for this to be a likely cause. The possibility that it represents an increase in the renal excretion of the hormone rather than in an increase in pituitary secretion has not, however, been tested. A further possibility that the ACTH was heavily contaminated with gonadotrophin and that this was excreted in the urine was excluded by assays of one of the effective batches of
